NetworkNewsBreaks – Applied Genetic Technologies Corp. (NASDAQ: AGTC) Secures $37.4M in Underwritten Public Offering
Applied Genetic Technologies (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (“AAV”)-based gene therapies for the treatment of rare diseases, has closed an underwritten public offering. According to the update, the offering consisted of 7,475,000 shares of its common stock, including an additional 975,000 shares pursuant to the full exercise of the over-allotment granted to the underwriters. Applied Genetic Technologies secured gross proceeds of approximately $37.4 million, with each of the shares sold at the public offering price of $5.00. ROTH Capital Partners acted as co-manager for the offering. To request access to the full report,…







